Bio-Rad Laboratories (BIO) FCF Margin (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported FCF Margin for 18 consecutive years, with 10.25% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin fell 62.0% year-over-year to 10.25% in Q2 2026; TTM through Jun 2026 was 13.64%, a 89.0% decrease from a year earlier, with the FY2025 full-year figure at 14.5%, up 322.0% from the prior year.
• FCF Margin was 10.25% for Q2 2026 at Bio-Rad Laboratories, down from 13.19% in the prior quarter.
• Over five years, FCF Margin peaked at 18.99% in Q3 2024 and troughed at 2.43% in Q3 2022.
• A 5-year average of 9.46% and a median of 9.27% in 2023 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin slumped 2864 bps in 2022 and soared 1147 bps in 2025, its largest moves.
• Over 5 years, FCF Margin stood at 6.13% in 2022, then retreated by 7 bps to 5.69% in 2023, then soared by 114 bps to 12.18% in 2024, then jumped by 41 bps to 17.18% in 2025, then plunged by 40 bps to 10.25% in 2026.
• The last three FCF Margin figures came in at 10.25% (Q2 2026), 13.19% (Q1 2026), and 17.18% (Q4 2025), per Business Quant data.